Endoscopic Gallbladder Stent Placement for Treatment of Symptomatic Cholelithiasis in Patients with End-Stage Liver Disease

Schlenker, Christine; Trotter, James F.; Shah, Raj J.; Everson, G.; Chen, Yang K.; Antillon, Daphne; Antillon, Mainor R.

doi:10.1111/j.1572-0241.2006.00403.x

Cited by 72 publications

(63 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several investigators have reported that ETGBD is effective and safe for patients with acute cholecystitis (6)(7)(8)17) and that EGBS is one of the promising alternative treatment options (9)(10)(11)(12)(13)(14)(15)(16)(17). In patients with concomitant unresectable cancer, it is important to control infectious diseases, including acute cholecystitis.…”

Section: Discussionmentioning

confidence: 99%

“…The goal for patients with concomitant unresectable cancer and acute cholecystitis is effective palliative short-term therapy by controlling infectious disease and maintaining quality of life. However, there are a few reports (9,11,13,14) of studies that evaluated the outcomes of long-term stent patency and adverse events in patients with acute cholecystitis who were contraindicated for cholecystectomy. Thus, in the present study, we evaluated the efficacy and safety of EGBS for patients with concomitant unresectable cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Endoscopic Gallbladder Stenting for Acute Cholecystitis in Patients with Concomitant Unresectable Cancer

et al. 2016

View full text Add to dashboard Cite

Objective Endoscopic gallbladder stenting (EGBS) is an alternative treatment option for high-risk surgical patients with acute cholecystitis. However, there are no reports focusing on EGBS in patients with concomitant unresectable cancer. The aim of this study was thus to evaluate EGBS in such patients. Methods Twenty-two consecutive patients with acute cholecystitis and unresectable cancer were enrolled between September 2010 and December 2014. Their median age was 74.5 years (range: 51-95). Thirteen patients were men and nine were women. The primary cancers of the patients were biliary tract cancer (9), pancreas cancer (9), lung cancer (2), gastric cancer (1), and colon cancer (1). The causes of cholecystitis were calculus cholecystitis (7), obstruction by malignant tumor (13), and obstruction by fully covered stent (2). Results EGBS was successfully performed in 17 patients (77.2%). The technical success rates for calculus cholecystitis, obstruction by malignant tumor, and obstruction by fully covered stent were 85.7% (6/7), 69.2% (9/13), and 100% (2/2), respectively. No complications were observed. Percutaneous transhepatic gallbladder drainage was conducted on two patients in whom EGBS had failed and then we performed EGBS by a rendezvous approach. Of the 19 patients in whom we finally deployed EGBS, the median follow-up period was 229 days (range: 14-880 days). A recurrence of acute cholecystitis occurred in three (15.7%) patients 14, 130, and 440 days after EGBS placement. The rates of recurrence of cholecystitis at one and two years were 10.5% and 18.7%, respectively. Conclusion Our study demonstrated that EGBS is a safe and effective method for acute cholecystitis in patients with concomitant unresectable cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Endoscopic Gallbladder Stenting for Acute Cholecystitis in Patients with Concomitant Unresectable Cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This complication is typically managed with cholecystectomy or placement of a cholecystostomy tube. Placement of transpapillary gallbladder stent (GBS) has been previously reported in patients with gallbladder cancer and acute cholecystitis [19][20][21][22][23][24]; however, not in the setting of bile duct stenting for distal biliary obstruction.…”

Section: Introductionmentioning

confidence: 99%

Gallbladder Stent Placement for Prevention of Cholecystitis in Patients Receiving Covered Metal Stent for Malignant Obstructive Jaundice: A Feasibility Study

et al. 2009

View full text Add to dashboard Cite

show abstract

“…To date, the stent has remained in situ without any complications for 7 mo of follow-up in this case. Because the patency results of the endoscopic gallbladder stent placement vary [8,9] , regular evaluation of stent patency may be also required in this particular case.…”

Section: Introductionmentioning

confidence: 99%

Endoscopic transcystic stent placement for an intrahepatic abscess due to gallbladder perforation

Kang

Park²,

Kwon³

et al. 2007

WJG

View full text Add to dashboard Cite

Endoscopic Gallbladder Stent Placement for Treatment of Symptomatic Cholelithiasis in Patients with End-Stage Liver Disease

Abstract: Endoscopic stenting of the gallbladder may be a potential treatment for symptomatic gallbladder disease in patients with cirrhosis awaiting liver transplantation, considered to be high-risk for cholecystectomy.

Cited by 72 publications

References 23 publications

Efficacy and Safety of Endoscopic Gallbladder Stenting for Acute Cholecystitis in Patients with Concomitant Unresectable Cancer

Efficacy and Safety of Endoscopic Gallbladder Stenting for Acute Cholecystitis in Patients with Concomitant Unresectable Cancer

Gallbladder Stent Placement for Prevention of Cholecystitis in Patients Receiving Covered Metal Stent for Malignant Obstructive Jaundice: A Feasibility Study

Endoscopic transcystic stent placement for an intrahepatic abscess due to gallbladder perforation

Contact Info

Product

Resources

About